
Augurex Life Sciences Corp.
- Home
- Companies
- Augurex Life Sciences Corp.
- News
- 10 Years of Peer-Reviewed Studies ...
10 Years of Peer-Reviewed Studies Predicting and Informing the Prognosis Profile of Autoimmune Patients
Nov. 10, 2021
Courtesy ofAugurex Life Sciences Corp.
Recent journal publications are fortifying the clinically important role of the 14-3-3η blood test along the whole continuum of RA and autoimmune patient care. From RA meta-analysis data through to 14-3-3η expression in juvenile idiopathic arthritis and secondary Sjögren’s syndrome in Lupus, the importance of this protein across a spectrum of autoimmune conditions is clear.
Stay in the loop!
Select your areas of interest to receive industry updates.